Disease · MONDO_0005487

schizoaffective disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. schizoaffective disorder. Diseases, record MONDO_0005487. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005487

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: schizoaffective disorder; Open Targets
Open Targets ID: MONDO_0005487; Open Targets
Disease Ontology: DOID:5418; Disease Ontology
NCI Thesaurus: C94378; NCI Thesaurus
Highest stage of its drugs: Approval, for 3 of its 103 drugs, from DailyMed; Open Targets

Drugs103

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PALIPERIDONE	CHEMBL1621	Small molecule	Approval	DailyMed	15	12	12	Drugs and targets
CLOZAPINE	CHEMBL42	Small molecule	Approval	DailyMed	16	6	6	Drugs and targets
PALIPERIDONE PALMITATE	CHEMBL2107360	Small molecule	Approval	DailyMed	3	2	2	Drugs and targets
RISPERIDONE	CHEMBL85	Small molecule	Phase 3	ClinicalTrials.gov	40	40	40	Drugs and targets
OLANZAPINE	CHEMBL715	Small molecule	Phase 3	ClinicalTrials.gov	16	16	16	Drugs and targets
ARIPIPRAZOLE	CHEMBL1112	Small molecule	Phase 3	ClinicalTrials.gov	11	11	11	Drugs and targets
QUETIAPINE	CHEMBL716	Small molecule	Phase 3	ClinicalTrials.gov	11	11	11	Drugs and targets
ZIPRASIDONE	CHEMBL708	Small molecule	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
LURASIDONE	CHEMBL1237021	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
(D)-SERINE	CHEMBL285123	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 103

See all 103 drugs

Targets140

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
DRD2	D(2) dopamine receptor	34	D2-like dopamine receptor agonist; D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor partial agonist; Dopamine receptor antagonist; Dopamine receptors; D2 & D3 antagonist	Approval	https://conductscience.org/library/genes/1813	Drugs and targets
HTR2A	5-hydroxytryptamine receptor 2A	27	Serotonin (5-HT) receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist	Approval	https://conductscience.org/library/genes/3356	Drugs and targets
DRD3	D(3) dopamine receptor	15	D2-like dopamine receptor agonist; D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist; Dopamine D3 receptor antagonist; Dopamine receptor antagonist; Dopamine receptors; D2 & D3 antagonist	Phase 3	https://conductscience.org/library/genes/1814	Drugs and targets
DRD4	D2-like dopamine receptor	12	D2-like dopamine receptor agonist; D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist; Dopamine receptor antagonist	Phase 3	https://conductscience.org/library/genes/1815	Drugs and targets
HTR2C	5-hydroxytryptamine receptor 2C	10	Serotonin (5-HT) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist	Phase 3	https://conductscience.org/library/genes/3358	Drugs and targets
HTR1A	5-hydroxytryptamine receptor 1A	6	Serotonin (5-HT) receptor antagonist; Serotonin 1a (5-HT1a) receptor agonist; Serotonin 1a (5-HT1a) receptor partial agonist	Phase 3	https://conductscience.org/library/genes/3350	Drugs and targets
ESR1	Estrogen receptor	3	Estrogen receptor alpha agonist; Estrogen receptor alpha modulator; Estrogen receptor modulator	Phase 3	https://conductscience.org/library/genes/2099	Drugs and targets
ADRA2A	Adrenergic receptor alpha-2	2	Adrenergic receptor alpha-2 agonist	Phase 3	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha-2	2	Adrenergic receptor alpha-2 agonist	Phase 3	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha-2	2	Adrenergic receptor alpha-2 agonist	Phase 3	https://conductscience.org/library/genes/152	Drugs and targets

1 to 10 of 140

See all 140 targets

Trials156

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02775864	Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia		81,921	2019-06-07	Schizophrenia, Schizoaffective Disorder	BENZODIAZEPINE	Its record names the disease	ClinicalTrials.gov
NCT00088465	Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder	Phase 3	931	2012-01-11	Schizophrenic Disorders, Schizoaffective Disorder	OLANZAPINE	Its record names the disease	ClinicalTrials.gov
NCT00216476	A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder	Phase 3	753	2010-08-10	Schizophrenia, Psychotic Disorders	ARIPIPRAZOLE, QUETIAPINE, RISPERIDONE	Its record names the disease	ClinicalTrials.gov
NCT01193153	A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder	Phase 3	667	2015-01-05	Schizoaffective Disorder	PALIPERIDONE PALMITATE	Its record names the disease	ClinicalTrials.gov
NCT00641745	Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia	Phase 3	629	2011-10-06	Schizophrenia, Schizoaffective Disorder	LURASIDONE, RISPERIDONE	Its record names the disease	ClinicalTrials.gov
NCT00132314	Long-Acting Injectable Risperidone in the Treatment of Schizophrenia	Phase 3	382	2013-12-20	Schizoaffective Disorder, Schizophrenia	RISPERIDONE	Its record names the disease	ClinicalTrials.gov
NCT04268303	Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia	Phase 3	380	2023-06-18	Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Schizophreniform Disorders	DEXMEDETOMIDINE	Its record names the disease	ClinicalTrials.gov
NCT00397033	Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.	Phase 3	316	2009-07-28	Schizoaffective Disorder, Psychotic Disorder	PALIPERIDONE	Its record names the disease	ClinicalTrials.gov
NCT00412373	Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.	Phase 3	307	2009-12-09	Schizoaffective Disorder, Psychotic Disorder	PALIPERIDONE	Its record names the disease	ClinicalTrials.gov
NCT04512066	A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder	Phase 2	287	2023-10-10	Schizophrenia, Schizoaffective Disorder	RALMITARONT, RISPERIDONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 156

See all 156 trials

Comparisons in its trials36

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Lurasidone vs Risperidone: Number of Participants With Adverse Events.	395 of 427	189 of 202	629	NCT00641745	Trial comparisons
Lurasidone vs Risperidone: serious adverse events	46 of 419	20 of 202	621	NCT00641745	Trial comparisons
Injectable Risperidone vs Oral Antipsychotic: serious adverse events	96 of 187	91 of 182	369	NCT00132314	Trial comparisons
Paliperidone Extended-Release (ER) vs Placebo: serious adverse events	11 of 214	8 of 95	309	NCT00412373	Trial comparisons
Paliperidone Extended-Release (ER) vs Placebo: Participants With Response	85 of 211	26 of 93	304	NCT00412373	Trial comparisons
Seroquel XR vs Risperidone: serious adverse events	4 of 109	4 of 107	216	NCT00640562	Trial comparisons
Seroquel XR vs Risperidone: Concomitant Use of Antidepressive Drugs From Baseline to Week 12	14 of 107	17 of 103	210	NCT00640562	Trial comparisons
Seroquel XR vs Risperidone: Concomitant Use of Antidepressive Drugs From Baseline to Week 12	12 of 107	11 of 103	210	NCT00640562	Trial comparisons
Varenicline vs Placebo: Number of Participants With 7-day Point Prevalence of Non-smoking at Week 12	16 of 84	2 of 43	127	NCT00644969	Trial comparisons
Varenicline vs Placebo: Number of Participants With 7-day Point Prevalence of Non-smoking at Week 24	10 of 84	1 of 43	127	NCT00644969	Trial comparisons

1 to 10 of 36

See all 36 comparisons in its trials

Papers from its trials108

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
28705532	RESULT	1	PubMed
28350572	RESULT	1	PubMed
27035157	RESULT	1	PubMed
25914107	RESULT	1	PubMed
25102328	RESULT	1	PubMed
24330868	RESULT	1	PubMed
24073841	RESULT	1	PubMed
23473656	RESULT	1	PubMed
23473350	RESULT	1	PubMed
23244442	RESULT	1	PubMed

1 to 10 of 108

See all 108 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005487

GET https://conductscience.org/api/diseases/v1/MONDO_0005487/drugs?page=2

API reference For AI assistants